Neoantigen Tracking: Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer (Adv. Sci. 9/2020)

Inter‐individual heterogeneity of the mutational spectrum is the major obstacle of effective in vivo monitoring of mutation‐directed T cell killing by ctDNA sequencing. In article number https://doi.org/10.1002/advs.201903410, Jianguo Sun, Bo Zhu, and co‐workers develop a customized sequencing strategy that mainly targets predicted neoantigen‐coding mutations. This work significantly broadens the coverage of ctDNA sequencing and is expected to improve personalized management strategies optimizing the clinical benefits of checkpoint immunotherapies. [Image: see text]